Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • HCC

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

    An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

    - PMLiVE

    AstraZeneca’s Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer

    Approximately 6,600 people are diagnosed with liver cancer every year in the UK

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

    The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

    - PMLiVE

    BMS receives FDA approval for immunotherapy combination in liver cancer

    Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

    - PMLiVE

    BMS granted EC approval for immunotherapy combination in liver cancer

    More than 866,100 cases of the disease were diagnosed globally in 2022

    - PMLiVE

    BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer

    Hepatocellular carcinoma accounts for approximately 90% of all liver cancer cases globally

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing

    The neurodegenerative disease affects almost seven million people in the US

    Biogen Idec building

    Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug

    The injection process for subcutaneous Leqembi is expected to take an average of 15 seconds

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation

    The neurodegenerative disorder affects an estimated 6.9 million people in Europe

    - PMLiVE

    AstraZeneca shares ‘unprecedented’ survival results for Imfinzi/Imjudo regimen in liver cancer

    Almost 900,000 new cases of liver cancer are diagnosed globally every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links